MENU
AARD
AS OF
Feb 4, 01:29 PM (EDT)
Price
$12.52
Change
-$0.39 (-3.02%)
Capitalization
281.53M
61 days until earnings call
Intraday BUY SELL Signals
+Compare
AARD
Stock ticker: NASDAQ
AS OF
Feb 4, 01:29 PM (EDT)
Price
$12.52
Change
-$0.39 (-3.02%)
Capitalization
281.53M

AARD Aardvark Therapeutics Inc Forecast, Technical & Fundamental Analysis

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases... Show more

AARD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for AARD with price predictions
Feb 03, 2026

Momentum Indicator for AARD turns negative, indicating new downward trend

AARD saw its Momentum Indicator move below the 0 level on January 27, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator turned negative. In of the 9 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for AARD moved out of overbought territory on January 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for AARD turned negative on January 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at .

AARD moved below its 50-day moving average on February 03, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AARD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AARD advanced for three days, in of 48 cases, the price rose further within the following month. The odds of a continued upward trend are .

AARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.300) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (331.843).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AARD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AARD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
AARD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

AARD is expected to report earnings to rise 6.67% to -80 cents per share on April 06

Aardvark Therapeutics Inc AARD Stock Earnings Reports
Q4'25
Est.
$-0.80
Q3'25
Beat
by $0.02
Q2'25
Beat
by $0.04
The last earnings report on November 13 showed earnings per share of -75 cents, beating the estimate of -76 cents. With 16.04K shares outstanding, the current market capitalization sits at 281.53M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SYANY18.10N/A
N/A
Sydbank A/S
UBEOF15.28N/A
N/A
UBE CORPORATION
ZDGGF0.10N/A
N/A
Zoo Digital Group Plc
BRIBF0.19N/A
N/A
BRII BIOSCIENCE LTD
IFNNY48.53-0.94
-1.90%
Infineon Technologies AG